SUBSCRIBE
SUBSCRIBE

Faraday Pharmaceuticals

NEWS
Business concept illustration of a businessman sitting contemplating on fallen arrow sign, bankruptcy, failure in business concept
Company closure
6 biotechs that called it quits in Q1
Six biotechs based in California, Massachusetts, Washington and Denmark had to halt drug development efforts this year. One of their CEOs is now in an interim chief executive role at another biotech.
April 30, 2026
 · 
6 min read
 · 
Angela Gabriel
Senior Female Scientist Works with High Tech Equipment in a Modern Laboratory. Her Colleagues are Working Beside Her.
Drug Development
Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio’s pediatric methylmalonic acidemia study is back up and running and another look at Roche’s TIGIT flop.
May 13, 2022
 · 
7 min read
 · 
Mark Terry
BioForest
Clinical Catch-Up: October 11-15
It was yet another busy week for clinical trial announcements. Take a look.
October 15, 2021
 · 
11 min read
 · 
Mark Terry
IN THE PRESS
Press Releases
Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury
April 25, 2025
 · 
5 min read
Press Releases
Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
February 5, 2025
 · 
1 min read
Press Releases
Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 6, 2024
 · 
1 min read
Drug Development
Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent
January 4, 2024
 · 
4 min read
Drug Development
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionIocyte AMI-3 Trial
May 10, 2022
 · 
4 min read
Drug Development
Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart AttackTo be Published in the International Journal of Cardiology
December 27, 2021
 · 
3 min read
Drug Development
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness
October 14, 2021
 · 
2 min read
Drug Development
Faraday Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Trial of FDY-5301 for Treatment of Reperfusion Injury Following a STEMI Heart Attack
November 19, 2019
 · 
3 min read
Drug Development
Faraday Pharmaceuticals Announces Presentation of Clinical Data from Phase 2 Trial of FDY-5301 at the American Heart Association Scientific Sessions 2019
November 12, 2019
 · 
1 min read
Drug Development
Faraday Pharma Announces First-In-Human Trial Of FDY-5301
September 23, 2016
 · 
1 min read
JOBS